- Record: found
- Abstract: found
- Article: found
Changes in Platelet Calcium Concentration by Thromboxane A 2 Stimulation in Patients with Nephrotic Syndrome of Childhood
Tomoyuki Kobayashi , Junzo Suzuki , Masakatu Watanabe , Sigeo Suzuki , Kazuo Yoshida , Kazunari Kume , Hitoshi Suzuki
23 December 2008
Ionized calcium, Thromboxane A2 , Nephrotic syndrome, Platelet
Abstract
In order to examine the intracellular thromboxane A<sub>2</sub> (TXA<sub>2</sub>) signal transduction system in platelets of patients with nephrotic syndrome, we measured the levels of TXA<sub>2</sub> metabolites in urine and blood and platelet calcium ion level as a result of STA2, an analog of STA<sub>2</sub> (9,11-dimethylmethano-11 12-methano-TXA<sub>2</sub>) stimulation, and obtained the following results: (1) In pediatric patients with nephrotic syndrome, urinary thromboxane B<sub>2</sub> (TXB<sub>2</sub>) and 11-dehydro-TXB<sub>2</sub> excretion were signficantly higher in the onset and relapse groups compared to the remission and control groups. (2) The blood 11-dehydro-TXB<sub>2</sub> level in the onset group was significantly higher than those in the remission and control groups. (3) Platelet calcium concentrations due to STA<sub>2</sub> stimulation were significantly increased in the onset, relapse and remission groups compared to the control group. These findings suggest activation of the TXA<sub>2</sub> signal transduction system in platelets of pediatric patients with nephrotic syndrome.
Related collections
Author and article information
Journal
Affiliations
Article
190293 Nephron 1997;77:309–314Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.